phrykt

Ironwood Pharmaceuticals Inc (IRWD): who owns it and who trades it

As of Nov 16, 2026, IRWD insiders reported 18 open-market sales worth $22.6M and no purchases in the last 12 months, with 0% of the sale value made under pre-set 10b5-1 plans. The largest seller was Alexander J Denner (Director), with $20.5M. 3 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Ironwood Pharmaceuticals

From the latest filings

Overall: more selling than buying. Insiders mostly sold. Famous investors mostly bought. Funds was close to even.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns IRWD

211 funds and institutions reported IRWD shares worth $689M at the end of Q2 2026, about 99% of the company. The largest holder is BlackRock, Inc. with 10.8%.

Funds and institutions (13F) 99%Everyone else 1%

10 largest owners, by share of the company

BlackRock, Inc.10.8%
Armistice Capital, LLC8.5%
Sarissa Capital Management LP5.6%
State Street Corp5.4%
Bank of America Corp5.3%
Renaissance Technologies LLC4.9%
Vanguard Capital Management LLC4.0%
AQR Capital Management LLC3.9%
Acadian Asset Management LLC3.6%
Vanguard Portfolio Management LLC3.3%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
BlackRock, Inc.17.79M10.81%$74.9M+33%
Armistice Capital, LLC13.93M8.46%$58.7M-7%
Sarissa Capital Management LP9.19M5.58%$38.7MNo change
State Street Corp8.81M5.35%$37.1M+18%
Bank of America Corp8.68M5.28%$36.6MNo change
Renaissance Technologies LLC7.99M4.86%$33.7M-1%
Vanguard Capital Management LLC6.61M4.01%$27.8M+8%
AQR Capital Management LLC6.47M3.93%$27.2M-14%
Acadian Asset Management LLC5.85M3.56%$24.6M-11%
Vanguard Portfolio Management LLC5.51M3.35%$23.2M-17%
Geode Capital Management, LLC4.83M2.94%$20.3M+6%
Two Sigma Investments, LP4.56M2.77%$19.2M-22%
Marshall Wace, LLP4.29M2.61%$18.1M-5%
Jacobs Levy Equity Management, Inc4.07M2.47%$17.1M+12%
Goldman Sachs Group Inc3.31M2.01%$14M+23%
Charles Schwab Investment Management Inc3.30M2.01%$13.9M-30%
Sixth Street Partners Management Company, L.P.3.30M2.01%$13.9M–
Federated Hermes, Inc.3.23M1.96%$13.6M-4%
Arrowstreet Capital, Limited Partnership3.02M1.83%$12.7M-11%
Dimensional Fund Advisors LP2.52M1.53%$10.6M+21%

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, IRWD insiders reported $0 of open-market purchases and $22.6M of sales. 0% of the sale value was under a 10b5-1 plan, a schedule set up in advance.

Purchases, 12 months
$0
0 trades, 0 people
Sales, 12 months
$22.6M
18 trades, 8 people
Sales under a 10b5-1 plan
0%
Share of sale value
Latest trade
Jul 7, 2026
Filed Jul 9, 2026

Purchases and sales by month

$20.5M$20.5MDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Jul 7, 2026Ronald SilverPFO & PAOSale127,890$4.52$578KForm 4
Jun 16, 2026Julie McHughDirectorSale21,571$3.73$80.5KForm 4
Mar 17, 2026Alexander J DennerDirectorSale5,800$3.31$19.2KForm 4
Mar 17, 2026Alexander J DennerDirectorSale6.72M$3.05$20.5MForm 4
Feb 24, 2026Gregory S. MartiniCFOSale11,457$3.66$41.9KForm 4
Feb 24, 2026Minardo JohnChief Legal OfficerSale19,053$3.66$69.7KForm 4
Feb 24, 2026Michael ShetzlineVice presidentSale17,012$3.66$62.3KForm 4
Feb 24, 2026Tammi L GaskinsChief Commercial OfficerSale11,239$3.66$41.1KForm 4
Feb 24, 2026Thomas A MCCOURTCEOSale103,526$3.66$379KForm 4
Feb 24, 2026Ronald SilverPrincipal Accounting OffSale12,621$3.66$46.2KForm 4
Feb 23, 2026Gregory S. MartiniCFOSale10,487$3.81$40KForm 4
Feb 23, 2026Minardo JohnChief Legal OfficerSale17,439$3.81$66.4KForm 4
Feb 23, 2026Michael ShetzlineVice presidentSale15,570$3.81$59.3KForm 4
Feb 23, 2026Tammi L GaskinsChief Commercial OfficerSale10,287$3.81$39.2KForm 4
Feb 23, 2026Thomas A MCCOURTCEOSale94,757$3.81$361KForm 4
Feb 23, 2026Ronald SilverPrincipal Accounting OffSale11,552$3.81$44KForm 4
Jan 5, 2026Ronald SilverPrincipal Accounting OffSale35,416$4.60$163KForm 4
Nov 17, 2025Tammi L GaskinsChief Commercial OfficerSale6,016$3.32$20KForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Alexander J DennerDirector–$20.5MMar 17, 2026
Ronald SilverPrincipal Accounting Officer–$831KJul 7, 2026
Thomas A MCCOURTChief Executive Officer, Director–$740KFeb 24, 2026
Minardo JohnChief Legal Officer–$136KFeb 24, 2026
Michael ShetzlineSVP, CMO, Head-Res&Drug–$122KFeb 24, 2026
Tammi L GaskinsChief Commercial Officer–$100KFeb 24, 2026
Gregory S. MartiniChief Financial Officer–$81.9KFeb 24, 2026
Julie McHughDirector–$80.5KJun 16, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

IRWD short interest

Moderate short interest. 9.0% of IRWD shares are sold short: about 1 share in 11. Over the last 12 reports the number of shares short went down 14%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 14.86M IRWD shares were sold short, 9.0% of the shares outstanding, down 6.5% from the report before. At the average daily volume of 1.51M shares, buying them all back would take about 9.8 trading days (days to cover).

Shares short, % of all shares

8.99%May 15Oct 3011.7%

Days to cover

9.8May 15Oct 3014.2

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 202614.86M8.99%-6%1.51M9.8
Oct 15, 202615.89M9.61%+2%1.99M8.0
Sep 30, 202615.57M9.42%-17%2.52M6.2
Sep 15, 202618.73M11.33%+6%1.43M13.1
Aug 31, 202617.65M10.68%-2%1.48M11.9
Aug 14, 202618.07M10.93%+9%2.80M6.4
Jul 31, 202616.54M10.01%-4%1.65M10.0
Jul 15, 202617.19M10.44%+6%2.72M6.3
Jun 30, 202616.23M9.86%+2%2.87M5.7
Jun 15, 202615.90M9.66%+6%1.94M8.2
May 29, 202615.02M9.12%-13%2.50M6.0
May 15, 202617.33M10.53%+0%3.00M5.8

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Ironwood Pharmaceuticals company events

Ironwood Pharmaceuticals filed 13 reports on Form 8-K in the last 12 months, 4 of them about an important change (leadership). The latest was on Nov 5, 2026.

  1. Nov 5, 2026ResultsReleased financial results. Filing
  2. Oct 16, 2026LeadershipIronwood Pharmaceuticals, Inc. today announced that, on October 12, 2026, the Board of Directors appointed Tammi Gaskins, the Company’s Senior Vice President, Chief Commercial Officer, as Chief Executive Officer, effective January 1, 2027. Filing
  3. Aug 6, 2026ResultsReleased financial results. Filing
  4. Jun 18, 2026LeadershipIronwood Pharmaceuticals, Inc. held its 2026 Annual Meeting of Stockholders. Filing
  5. Jun 15, 2026AnnouncementIronwood Pharmaceuticals, Inc. repaid in full the $200.0 million of its 1.50% convertible senior notes due 2026 at their scheduled maturity. Filing
  6. May 21, 2026LeadershipAmended an earlier report. In connection with Mr. Silver’s new role as the Company’s interim chief financial officer and principal financial officer, the Committee approved a monthly interim assignment fee of $12,250 for Mr. Silver. Filing
  7. May 13, 2026LeadershipGregory Martini notified Ironwood Pharmaceuticals, Inc. that he is resigning from his position as Senior Vice President, Chief Financial Officer, effective May 15, 2026. Filing
  8. May 7, 2026ResultsReleased financial results. Filing
  9. Mar 11, 2026AnnouncementIronwood Pharmaceuticals, Inc. notified Wells Fargo Bank, National Association, as administrative agent (in such capacity, the “Agent”), under the Credit Agreement, dated May 21, 2023, as amended by Amendment No. 1 to Credit Agreement, dated September 27, 2024 (the “Amended Credit Agreement,” and… Filing
  10. Feb 25, 2026ResultsReleased financial results. Filing
  11. Jan 2, 2026ResultsReleased financial results. Filing
  12. Dec 23, 2025AgreementIronwood Pharmaceuticals, Inc., solely for purposes of a limited payment guarantee, VectivBio AG, a wholly owned subsidiary of the Company, and Ferring International Center S.A., entered into that certain third amendment to the amended and restated exclusive license agreement, dated as of December… Filing
  13. Nov 26, 2025AnnouncementThe U.S. Department of Health and Human Services released the “Maximum Fair Price” for LINZESS® (linaclotide), which was selected in the most recent round of government price setting as part of the Inflation Reduction Act of 2022. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Ironwood Pharmaceuticals financials

Famous investors that hold IRWD

3 of the 50 well-known investors we track reported holding IRWD in their latest 13F filing. The largest position is Jim Simons's, worth $31.9M.

Position size

All holders

FundQuarterSharesValueOf portfolioChange
Jim Simons · Renaissance TechnologiesQ3 20268.04M$31.9M0.0%+1%
Ken Griffin · Citadel AdvisorsQ3 2026299,721$1.2M0.0%-40%
Israel Englander · Millennium ManagementQ3 202680,796$321K0.0%New

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 6 filings named IRWD in the last 120 days.

FiledHolderFormStake
Nov 16, 2026Armistice Capital, LLC13G/A9.1%
Nov 16, 2026Armistice Capital, LLC13G/A9.1%
Nov 10, 2026STATE STREET CORPORATION13G4.1%
Nov 10, 2026STATE STREET CORPORATION13G4.1%
Oct 28, 2026BANK OF AMERICA CORP /DE/13G/A3.2%
Oct 28, 2026BANK OF AMERICA CORP /DE/13G/A3.2%

Questions about Ironwood Pharmaceuticals Inc (IRWD) stock

Who owns the most IRWD stock?

The largest reported owner of Ironwood Pharmaceuticals Inc (IRWD) is BlackRock, Inc., with 10.8% of the company. In total, 211 funds and institutions reported holding IRWD at the end of Q2 2026, together about 99% of the shares. See the largest owners.

Are IRWD insiders buying or selling?

In the last 12 months, IRWD insiders reported no open-market purchases and 18 sales worth $22.6M. The latest trade was on Jul 7, 2026. See every trade.

What is the short interest in IRWD?

As of Oct 30, 2026, 14.86M IRWD shares were sold short, 9.0% of the shares outstanding, down 6.5% from the report before. At the average daily volume of 1.51M shares, buying them all back would take about 9.8 trading days (days to cover). See the history.

Which famous investors hold IRWD?

3 of the 50 well-known investors we track reported IRWD in their latest 13F filing, including Jim Simons, Ken Griffin, Israel Englander. The largest position is worth $31.9M. See all holders.

Executive pay

Ironwood Pharmaceuticals's chief executive was paid a total of $1.9M for the year ended Dec 31, 2025, down 68% from $6.1M the year before. In the last 12 months, Ironwood Pharmaceuticals's executives and directors bought no stock on the open market and sold $22.6M.

Chief executive, total pay$1.9MYear ended Dec 31, 2025. Salary, bonus and the value of stock and option awards when granted.
Pay "actually paid"$1.3MThe same year, with stock awards valued at what they were worth as they vested or at year end.
Other top executives, average$1.2MThe other officers named in the proxy statement.

From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.